Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Rule

Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community

A Rule by the Food and Drug Administration on 02/19/2026

• 1.

1.

• Document Details Published Content - Document Details Agencies Department of Health and Human Services Food and Drug Administration Agency/Docket Number Docket No. FDA-2024-N-4016 CFR 21 CFR 26 Document Citation 91 FR 7825 Document Number 2026-03286 Document Type Rule Pages 7825-7829
  (5 pages) Publication Date 02/19/2026 RIN 0910-AI92 Published Content - Document Details

• PDF Official Content

  • View printed version (PDF) Official Content

• Document Details Published Content - Document Details Agencies Department of Health and Human Services Food and Drug Administration Agency/Docket Number Docket No. FDA-2024-N-4016 CFR 21 CFR 26 Document Citation 91 FR 7825 Document Number 2026-03286 Document Type Rule Pages 7825-7829
  (5 pages) Publication Date 02/19/2026 RIN 0910-AI92 Published Content - Document Details

• Document Dates Published Content - Document Dates Effective Date 2026-03-23 Dates Text This rule is effective March 23, 2026. Published Content - Document Dates

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  • AGENCY:
  • ACTION:
  • SUMMARY:
  • DATES:
  • ADDRESSES:
  • FOR FURTHER INFORMATION CONTACT:
  • SUPPLEMENTARY INFORMATION:
  • Table of Contents
  • I. Executive Summary
  • A. Purpose of the Final Rule
  • B. Summary of the Major Provisions of the Final Rule
  • C. Legal Authority
  • D. Costs and Benefits
  • II. Table of Abbreviations/Commonly Used Acronyms in This Document
  • III. Background
  • A. Need for the Regulation/History of This Rulemaking
  • B. Summary of Comments to the Proposed Rule
  • IV. Legal Authority
  • V. Comments on the Proposed Rule and FDA Response
  • A. Introduction
  • B. Description of General Comments and FDA Response
  • C. Specific Comments and FDA Response
  • VI. Effective Date/Compliance Date(s)
  • VII. Economic Analysis of Impacts
  • A. Introduction
  • B. Overview of Benefits, Costs, and Transfers
  • VIII. Analysis of Environmental Impact
  • IX. Paperwork Reduction Act of 1995
  • X. Federalism
  • XI. Consultation and Coordination With Indian Tribal Governments
  • List of Subjects in 21 CFR Part 26
  • PART 26—[REMOVED] Enhanced Content - Table of Contents

• Related Documents Enhanced Content - Related Documents FederalRegister.gov uses the agency dockets published with the document to display related documents.

| Docket No. FDA-2024-N-4016
(2 Documents) | | | |
| --- | | | |
| Date | | Action | Title |
| | 2026-02-19 | Final rule. | Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community |
| | 2024-09-20 | Proposed rule. | Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community |

Enhanced Content - Related Documents

• Public Comments Enhanced Content - Public Comments Comments are no longer being accepted. See DATES for details.

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data

FederalRegister.gov retrieves relevant information about this document
from Regulations.gov to provide users with additional context. This
information is not part of the official Federal Register document.

Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community

Docket ID FDA-2024-N-4016 Supporting Documents No supporting documents available Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2026-03286 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Print this document Enhanced Content - Print
• Document Statistics Enhanced Content - Document Statistics Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.

Page views 410
as of
02/26/2026 at 8:15 am EST Enhanced Content - Document Statistics
- Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2026-03286 as it appeared on Public Inspection on
02/18/2026 at 8:45 am.

It was viewed
74
times while on Public Inspection.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2026-03286 (91 FR 7825) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Department of Health and Human Services

Food and Drug Administration

1. 21 CFR Part 26
2. [Docket No. FDA-2024-N-4016]
3. RIN 0910-AI92

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA, Agency, or we) is issuing a final rule revoking the regulations entitled “Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community.” FDA is taking this action because the ( printed page 7826) regulations at 21 CFR part 26 have been superseded in part by the “United States-European Union Amended Sectoral Annex for Pharmaceutical Good Manufacturing Practices (GMPs)” that entered into force in 2017 (2017 Amended Pharmaceutical Annex), are outdated, do not reflect current Agency practice, and are unnecessary.

DATES:

This rule is effective March 23, 2026.

ADDRESSES:

For access to the docket to read background documents or comments received, go to https://www.regulations.gov and insert the docket number found in brackets in the heading of this final rule into the “Search” box and follow the prompts, and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT:

Megan Andersen, Office of Inspections and Investigations, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, 202-684-5901, megan.andersen@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

Table of Contents

I. Executive Summary

A. Purpose of the Final Rule

B. Summary of the Major Provisions of the Final Rule

C. Legal Authority

D. Costs and Benefits

II. Table of Abbreviations/Commonly Used Acronyms in This Document

III. Background

A. Need for the Regulation/History of This Rulemaking

B. Summary of Comments to the Proposed Rule

IV. Legal Authority

V. Comments on the Proposed Rule and FDA Response

A. Introduction

B. Description of General Comments and FDA Response

C. Specific Comments and FDA Response

VI. Effective Date/Compliance Date(s)

VII. Economic Analysis of Impacts

A. Introduction

B. Overview of Benefits, Costs, and Transfers

VIII. Analysis of Environmental Impact

IX. Paperwork Reduction Act of 1995

X. Federalism

XI. Consultation and Coordination With Indian Tribal Governments

XII. References

I. Executive Summary

A. Purpose of the Final Rule

FDA is revoking the regulations at part 26 (21 CFR part 26), which substantially reflect certain provisions of the “Agreement on Mutual Recognition Between the United States of America and the European Community” that was signed in 1998 (1998 MRA). These regulations have been superseded in part by the 2017 Amended Pharmaceutical Annex, are outdated, do not reflect current Agency practice, and are unnecessary.

B. Summary of the Major Provisions of the Final Rule

The final rule revokes part 26, “Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and The European Community.” This part substantially reflects certain provisions of the 1998 MRA between the United States and the European Community (EC) that were created to better utilize the inspectional resources of each signatory by recognizing one another's inspection reports. Part 26 consists of 3 subparts: Subpart A—Specific Sector Provisions for Pharmaceutical Good Manufacturing Practices (which substantially reflects the 1998 MRA's “pharmaceutical sectoral annex”), Subpart B—Specific Sector Provisions for Medical Devices (which substantially reflects the 1998 MRA's “medical device sectoral annex”), and Subpart C—“Framework” Provisions (which substantially reflects the 1998 MRA's “umbrella” agreement that contained general provisions applicable to the operation of all of the sectoral annexes).

C. Legal Authority

FDA is taking this action under the general administrative provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (see generally 21 U.S.C. 301-399). We discuss our legal authority in greater detail in part IV.

D. Costs and Benefits

Because this final rule would not impose any additional regulatory burdens, this regulation is not anticipated to result in any compliance costs and the economic impact, if any, is expected to be minimal.

II. Table of Abbreviations/Commonly Used Acronyms in This Document

| Abbreviation | What it means |
| --- | --- |
| EC | European Community. |
| EU | European Union. |
| FD&C Act | Federal Food, Drug, and Cosmetic Act. |
| GMP | Good Manufacturing Practice. |
| MRA | Mutual Recognition Agreement. |

III. Background

A. Need for the Regulation/History of This Rulemaking

Part 26 was issued in response to the 1998 MRA between the United States and the EC, under which both parties would recognize certain drug and device inspection/evaluation reports of the other, in order to more effectively allocate limited inspection resources (Mutual Recognition of Pharmaceutical Good Manufacturing Practice Inspection Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports Between the United States and the European Community, 63 FR 60122 at 60141 (November 6, 1998)). Subparts A and B of part 26 substantially reflect the 1998 MRA's pharmaceutical and medical device sectoral annexes, respectively. Subpart C of part 26 sets forth the framework provisions by which Subparts A and B can be implemented. Subpart A governs “the exchange between the parties and normal endorsement by the receiving regulatory authority of official [pharmaceutical] good manufacturing practices (GMP) inspection reports[.]” (21 CFR 26.2). Subpart B specifies “the conditions under which a party will accept the results of quality system-related evaluations and inspections and premarket evaluations of the other party with regard to medical devices as conducted by listed conformity assessment bodies (CAB's)” and provides for “other related cooperative activities.” (21 CFR 26.31(a)).

The pharmaceutical sectoral annex to the 1998 MRA was superseded by the 2017 Amended Pharmaceutical Annex (https://www.fda.gov/​international-programs/​international-arrangements/​mutual-recognition-agreements-mra). The 2017 Amended Pharmaceutical Annex included new terms, rendering Subpart A obsolete. The medical device sectoral annex was not addressed in the 2017 Amended Pharmaceutical Annex, but since the 1998 MRA went into effect, it has never been fully implemented. As other mechanisms (e.g., Medical Device Single Audit Program) now exist for mutual recognition with Europe with respect to medical device inspections, Subpart B is no longer necessary. Subpart C contains general provisions applicable to both Subparts A and B that will be unnecessary once Subparts A and B are revoked.

FDA published a notice of proposed rulemaking that would revoke 21 CFR part 26 in the Federal Register on September 20, 2024 (89 FR 77062). The public was invited to submit electronic ( printed page 7827) or written comments during the comment period, which closed on November 19, 2024.

B. Summary of Comments to the Proposed Rule

FDA received eight submissions on the proposed rule by the close of the 60-day comment period with each containing one or more comments on one or more issues. Some of the comments were submitted by individuals and some were submitted anonymously. Some of the comments supported the proposed rule while others were opposed to the proposed rule.

IV. Legal Authority

We are issuing this final rule under the drugs, medical devices, and general administrative provisions of the FD&C Act (21 U.S.C. 321, 331, 351, 352, 355, 360, 360b, 360c, 360d, 360e, 360f, 360g, 360h, 360i, 360j, 360l, 360m, 371, 374, 381, 382, 383, 384e, and 393) and under certain provisions of the Public Health Service Act (42 U.S.C. 216, 241, 242l, 262, 264, and 265). Under section 701(a) of the FD&C Act (21 U.S.C. 371(a)), FDA has the authority to issue regulations, and under section 809 of the FD&C Act (21 U.S.C. 384e), FDA has the authority to “enter into arrangements and agreements with a foreign government or an agency of a foreign government to recognize the inspection of foreign establishments registered under section 510(i) in order to facilitate preapproval or risk-based inspections in accordance with the schedule established in paragraph (2) or (3) of section 510(h)[.]”

V. Comments on the Proposed Rule and FDA Response

A. Introduction

We received eight comment submissions on the proposed rule by the close of comment period, with each containing one or more comments on one or more issues. Some of the comments were submitted by individuals while others were submitted anonymously.

We describe and respond to the comments in section V.B. and V.C. of this document. We have numbered each comment to help distinguish between different comments. We have grouped similar comments together under the same number, and in some cases, we have separated different issues discussed in the same comment and designated them as distinct comments for purposes of our responses. The number assigned to each comment or comment topic is purely for organizational purposes and does not signify the comment's value or importance or the order in which comments were received.

We also received several comments that were not responsive to the content of the proposed rule, and therefore, were not considered in its final development. After reviewing and considering all comments that were responsive to the proposed rule, we are finalizing the proposed rule without change.

B. Description of General Comments and FDA Response

Several comments make general remarks either supporting or opposing the proposed rule. In the following paragraphs, we discuss and respond to such general comments.

(Comment 1) Three comments are in support of finalizing the proposed rule and recommend FDA provide clear guidance about the changes and their impact to help maintain compliance and uphold high safety and quality standards.

(Response 1) We agree with the comments and in the proposed rule we stated that the rule would not impose any new changes or additional regulatory burdens. The rule is not anticipated to result in any compliance costs and the economic impact, if any, is expected to be minimal.

C. Specific Comments and FDA Response

(Comment 2) One comment asks how an MRA has the force of law such that it could supersede a regulation for which the American public received advanced notice and opportunity to comment.

(Response 2) MRAs are agreements between two or more countries or regulatory counterparts to recognize certain processes or procedures. In the context of FDA, MRAs have generally focused on recognizing the inspections and accepting the inspectional documents of foreign regulatory authorities. FDA's current MRAs, including the 2017 Amended Pharmaceutical Annex, are binding international agreements entered into by the United States. (22 CFR 181.2) In 2012, the 112th Congress passed, and the President signed into law, Title VII of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144 ) amending the FD&C Act. Under the FD&C Act as amended, FDA itself has the authority to enter into agreements to recognize inspections conducted by foreign regulatory authorities if FDA determines those authorities are capable of conducting inspections that meet the applicable requirements of the FD&C Act.

When the United States entered into an MRA with the EC in 1998, FDA issued part 26, which substantially reflects certain provisions of the 1998 MRA. Under 21 CFR 26.80(b), the 1998 MRA can be “amended in writing by the parties to that agreement.” In 2017, the 1998 MRA was amended through an exchange of letters between the United States and the European Union (EU).

The regulations at part 26 also provide that “[i]f the parties to the MRA subsequently amend or terminate the MRA, FDA will modify this part accordingly, using appropriate administrative procedures[.]” (21 CFR 26.0). We have determined that this rulemaking is an appropriate procedure for revoking the regulations at part 26.

As we explained in the proposed rule, we do not believe it is required or would be beneficial for FDA to issue regulations that substantially reflect the 2017 Amended Pharmaceutical Annex with the EU. The 2017 Amended Pharmaceutical Annex is in force and has been successfully implemented without regulations that substantially reflect it. The same is true for the MRAs that the United States entered into subsequently with Switzerland and the United Kingdom (https://www.fda.gov/​international-programs/​international-arrangements/​mutual-recognition-agreements-mra).

(Comment 3) One comment asserts that revoking the MRA on pharmaceutical inspections would lead to increased costs, reduced access to affordable medications, and potentially less international collaboration.

(Response 3) This rule does not revoke an MRA. This rule revokes the regulations that substantially reflect certain provisions of the 1998 MRA. As noted, in 2017, the United States and the EU completed an exchange of letters to amend the 1998 MRA. Under the 2017 Amended Pharmaceutical Annex, which is in force and has been successfully implemented, United States and EU regulators are able to utilize each other's GMP inspections of pharmaceutical manufacturing facilities. FDA's revocation of part 26 should not be interpreted as FDA retreating from our commitment to working with our foreign counterparts, including through MRAs, to achieve greater efficiencies and increase our inspectional reach.

VI. Effective Date/Compliance Date(s)

This final rule is effective 30 days after publication in the Federal Register. ( printed page 7828)

VII. Economic Analysis of Impacts

A. Introduction

We have examined the impacts of the final rule under Executive Order 12866, Executive Order 13563, Executive Order 14192, the Regulatory Flexibility Act (5 U.S.C. 601-612), the Congressional Review Act/Small Business Regulatory Enforcement Fairness Act (5 U.S.C. 801, Pub. L. 104-121), and the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4).

Executive Orders 12866 and 13563 direct us to assess all benefits and costs of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits. Rules are “significant” under Executive Order 12866 if they have an annual effect on the economy of $100 million or more; or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities. The Office of Information and Regulatory Affairs (OIRA) has determined that this final rule is not a significant regulatory action under Executive Order 12866.

Executive Order 14192 requires that any new incremental costs associated with certain significant regulatory actions “shall, to the extent permitted by law, be offset by the elimination of existing costs associated with at least 10 prior regulations.” This final rule is considered an Executive Order 14192 deregulatory action.

Because this rule is not likely to result in an annual effect on the economy of $100 million or more or meets other criteria specified in the Congressional Review Act/Small Business Regulatory Enforcement Fairness Act, OIRA has determined that this rule does not fall within the scope of 5 U.S.C. 804(2).

The Regulatory Flexibility Act requires us to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because this final rule does not add any new regulatory burden on the pharmaceutical or medical device industries, we certify that the final rule will not have a significant economic impact on a substantial number of small entities.

The Unfunded Mandates Reform Act of 1995 (section 202(a)) requires us to prepare a written statement, which includes estimates of anticipated impacts, before issuing “any rule that includes any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted annually for inflation) in any one year.” The current threshold after adjustment for inflation is $187 million, using the most current (2024) Implicit Price Deflator for the Gross Domestic Product. This final rule will not result in an expenditure in any year that meets or exceeds this amount.

B. Overview of Benefits, Costs, and Transfers

We believe industry will maintain its current practices following the removal of part 26. In line with Executive Order 14192, in Table 1 we estimate present and annualized values of costs, cost savings, and net costs over a perpetual time horizon. We estimate that this rule will generate no quantifiable costs or cost savings. Therefore, we expect this final rule to be cost neutral.

| Category | Primary
estimate | Low
estimate | High
estimate | Units | | | Notes |
| --- | --- | --- | --- | --- | --- | | |
| Year
dollars | Discount
rate
(%) | Period
covered
(years) | | | | | |
| Benefits: | | | | | | | |
| Annualized Monetized $millions/year | $0
0 | $0
0 | $0
0 | 2024
2024 | 7
3 | 10
10 | |
| Annualized Quantified | | | | | | | |
| Qualitative | Avoid confusion created by outdated and unnecessary regulations that do not reflect current Agency practice. | | | | | | |
| Costs: | | | | | | | |
| Annualized Monetized $millions/year | 0
0 | 0
0 | 0
0 | 2024
2024 | 7
3 | 10
10 | |
| Annualized Quantified | | | | | 7
3 | | |
| Qualitative | | | | | | | |
| Transfers: | | | | | | | |
| Federal Annualized Monetized $millions/year | | | | | 7
3 | | |
| From/To | From: | | | To: | | | |
| Other Annualized Monetized $millions/year | | | | | 7
3 | | |
| From/To | From: | | | To: | | | |
| Effects: | | | | | | | |
| State, Local or Tribal Government: No estimated effect. | | | | | | | |
| Small Business: No estimated effect. | | | | | | | |
| Wages: No estimated effect. | | | | | | | |
| Growth: No estimated effect. | | | | | | | |
( printed page 7829) In line with Executive Order 14192, in Table 2 we estimate present and annualized values of costs, cost savings, and net costs over a perpetual time horizon. We estimate that this rule will generate $0 in annualized net costs at a 7 percent discount rate, discounted relative to year 2024, over a perpetual time horizon.

| | Primary
(7%) | Lower bound
(7%) | Upper bound
(7%) |
| --- | --- | --- | --- |
| Present Value of Costs | $0 | $0 | $0 |
| Present Value of Cost Savings | 0 | 0 | 0 |
| Present Value of Net Costs | 0 | 0 | 0 |
| Annualized Costs | 0 | 0 | 0 |
| Annualized Cost Savings | 0 | 0 | 0 |
| Annualized Net Costs | 0 | 0 | 0 |

VIII. Analysis of Environmental Impact

We have determined under 21 CFR 25.31(h) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

IX. Paperwork Reduction Act of 1995

This final rule contains no collection of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required.

X. Federalism

We have analyzed this final rule in accordance with the principles set forth in Executive Order 13132. We have determined that the rule does not contain policies that have substantial direct effects on the States, on the relationship between the National Government and the States, or on the distribution of power and responsibilities among the various levels of government. Accordingly, we conclude that the rule does not contain policies that have federalism implications as defined in the Executive Order and, consequently, a federalism summary impact statement is not required.

XI. Consultation and Coordination With Indian Tribal Governments

We have analyzed this rule in accordance with the principles set forth in Executive Order 13175. We have determined that this final rule does not contain policies that have substantial direct effects on one or more Indian Tribes, on the relationship between the Federal Government and Indian Tribes, or on the distribution of power and responsibilities between the Federal Government and Indian Tribes. Accordingly, we conclude that the rule does not contain policies that have tribal implications as defined in the Executive Order and, consequently, a tribal summary impact statement is not required.

List of Subjects in 21 CFR Part 26

• Animal
• Animal drugs
• Biologics
• Drugs
• Exports
• Imports

PART 26—[REMOVED]

Therefore, under the Federal Food, Drug, and Cosmetic Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 26 is removed.

Robert F. Kennedy, Jr.,

Secretary, Department of Health and Human Services.

[FR Doc. 2026-03286 Filed 2-18-26; 8:45 am]

BILLING CODE 4164-01-P

Published Document: 2026-03286 (91 FR 7825)